000 01365 a2200385 4500
005 20250515015935.0
264 0 _c20060420
008 200604s 0 0 eng d
022 _a1389-4501
024 7 _a10.2174/138945006776054997
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aVassilev, Alexei O
245 0 0 _aTargeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors.
_h[electronic resource]
260 _bCurrent drug targets
_cMar 2006
300 _a327-43 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAgammaglobulinaemia Tyrosine Kinase
650 0 4 _aAnimals
650 0 4 _aAutoimmune Diseases
_xdrug therapy
650 0 4 _aDiabetes Mellitus, Type 1
_xdrug therapy
650 0 4 _aDrug Delivery Systems
650 0 4 _aDrug Design
650 0 4 _aEnzyme Inhibitors
_xpharmacology
650 0 4 _aHumans
650 0 4 _aJanus Kinase 3
650 0 4 _aNeoplasms
_xcomplications
650 0 4 _aOrgan Transplantation
_xphysiology
650 0 4 _aProtein-Tyrosine Kinases
_xantagonists & inhibitors
700 1 _aTibbles, Heather E
700 1 _aDuMez, Darin
700 1 _aVenkatachalam, Taracad K
700 1 _aUckun, Fatih M
773 0 _tCurrent drug targets
_gvol. 7
_gno. 3
_gp. 327-43
856 4 0 _uhttps://doi.org/10.2174/138945006776054997
_zAvailable from publisher's website
999 _c16125568
_d16125568